Stock Pulse
Zoetis (ZTS) reported Q4 2024 revenue of $2.32 billion, a 4.7% year-over-year increase, meeting expectations, but significantly missed full-year EPS guidance [2], [8]. This miss contributed to a stock decline of over 10% in the past week, exacerbated by broader market downturn [1], [2]. Despite this, analysts predict annual revenue growth of 4.6% and increasing profit margins over the next three years [1]. The company's 2024 performance showed strong revenue growth driven by its companion animal portfolio [3], [6], but 2025 guidance is weaker due to anticipated competition [6]. Long-term prospects remain positive due to continued investments in areas like pet pain management and dermatology [1], along with a history of innovation and strategic acquisitions such as Basepaws [4]. However, the EPS miss raises concerns about profitability and short-term performance [2], [8].